Skip to main content
SpringerLink
Log in

Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery Disease

Implications for Clinical Practice

  • Genomics in Health and Disease
  • Published:
American Journal of Pharmacogenomics

Abstract

Membrane glycoprotein (GP) IIb/IIIa plays a major role in platelet function; indeed it enables stimulated platelets to bind fibrinogen and related adhesive proteins, a process that is considered key in the development of thrombosis. The gene encoding GPIIIa (ITGB3, also known as GP3A) shows a common platelet antigen polymorphism [PL(A1)/PL(A2); expressed by alleles ITGB3*001 and ITGB3*002] that was variably associated with vascular disease. In 1996, the presence of the PL(A2) allele (ITGB3*001) was first reported to increase the risk of coronary heart disease. Shortly after, the interest in this study was increased by the publication of a case report on the death from myocardial infarction of an Olympic athlete who was found to be homozygous for the PL(A2) allele. Overviews of the published studies on the PL(A1)/PL(A2) polymorphism and coronary risk suggest an influence of the PL(A2) allele on the clinical phenotype and the interaction with other environmental factors. In particular, the strongest effect of the ITGB3 PL(A2) allele was expressed on the risk of occlusion after revascularization procedures, mainly after stent implantation, a condition in which platelet activation is more important as compared with other stenotic mechanisms.

In the future, the identification of patients who are particularly responsive to GPIIb/IIIa antagonist therapy (e.g. those with the PL(A2) allele) might help to improve the treatment efficacy in this relatively small population. In a mechanism possibly unrelated to its effect on platelet reactivity to aggregating stimuli, the presence of the PL(A2) allele might influence the antiaggregatory effect of platelet inhibitory drugs such as aspirin (acetylsalicylic acid), clopidogrel, and GPIIb/IIIa antagonists.

Although interesting, current data does not yet have direct clinical implications for patient risk identification and drug therapy tailoring. Larger studies are necessary to define the role of the PL(A2) allele in more homogeneous groups where platelet GPIIb/IIIa activation might be particularly relevant.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Peerschke EIB, Lopez JA. Platelet membranes and receptors. In: Loscalzo J, Schafer AI, editors. Thrombosis and hemorrhage. 2nd ed. Baltimore (MD): Williams & Wilkins, 1998: 229

    Google Scholar 

  2. Andrews RK, Shen Y, Gardiner EE, et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82: 357–64

    PubMed  CAS  Google Scholar 

  3. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553–9

    Article  PubMed  CAS  Google Scholar 

  4. Nurden AT. Polymorphisms of human platelet membrane glycoproteins: structure and clinical significance. Thromb Haemost 1995; 74: 345–51

    PubMed  CAS  Google Scholar 

  5. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992; 80: 1386–404

    PubMed  CAS  Google Scholar 

  6. Newman PJ. Platelet alloantigens: cardiovascular as well as immunological risk factors? Lancet 1997; 349: 370–1

    Article  PubMed  CAS  Google Scholar 

  7. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090–4

    Article  PubMed  CAS  Google Scholar 

  8. Goldschmidt-Clermont PJ, Shear WS, Schwartzberg J, et al. Clues to the death of an Olympic champion [letter]. Lancet 1996; 347: 1833

    Article  PubMed  CAS  Google Scholar 

  9. Di Castelnuovo A, de Gaetano G, Donati MB, et al. Platelet glycoprotein receptor IIIa polymorphism PL(A1)/PL(A2) and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 626–33

    PubMed  Google Scholar 

  10. Ridker PM, Hennekens CH, Schmitz C, et al. Pl(A1)/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet 1997; 349: 385–8

    Article  PubMed  CAS  Google Scholar 

  11. Aleksic N, Juneja H, Folsom AR, et al. Platelet Pl(A2) allele and incidence of coronary heart disease: results from the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2000; 102: 1901–5

    Article  PubMed  CAS  Google Scholar 

  12. Bray PF, Cannon CP, Goldschmidt-Clermont P, et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88: 347–52

    Article  PubMed  CAS  Google Scholar 

  13. Mikkelsson J, Perola M, Penttila A, et al. The GPIIIa (β3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 2001; 154: 721–7

    Article  PubMed  CAS  Google Scholar 

  14. Mikkelsson J, Perola M, Laippala P, et al. Glycoprotein IIIa Pl (A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 2000; 36: 1317–23

    Article  PubMed  CAS  Google Scholar 

  15. Grove EL, Orntoft TF, Lassen JF, et al. The platelet polymorphism Pl(A2) is a genetic risk factor for myocardial infarction. J Intern Med 2004; 255: 637–44

    Article  PubMed  CAS  Google Scholar 

  16. Doll R. The use of meta-analysis in epidemiology: diet and cancers of the breast and colon. Nutr Rev 1994; 52: 233–7

    Article  PubMed  CAS  Google Scholar 

  17. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa Pl(A1)/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86: 1000–5

    Article  PubMed  CAS  Google Scholar 

  18. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol 2001; 87: 1361–6

    Article  PubMed  CAS  Google Scholar 

  19. Burr D, Doss H, Cooke GE, et al. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003; 22: 1741–60

    Article  PubMed  Google Scholar 

  20. Eriksson P, Kallin B, van’t Hooft FM, et al. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995; 92: 1851–5

    Article  PubMed  CAS  Google Scholar 

  21. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817–21

    PubMed  CAS  Google Scholar 

  22. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003; 107: 1117–22

    Google Scholar 

  23. Bojesen SE, Juul K, Schnohr P, et al. Platelet glycoprotein IIb/IIIa Pl(A2)/Pl(A2) homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study. J Am Coll Cardiol 2003 Aug 20; 42: 661–7

    Article  PubMed  CAS  Google Scholar 

  24. Kastrati A, Schomig A, Seyfarth M, et al. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999; 99: 1005–10

    Article  PubMed  CAS  Google Scholar 

  25. Pastinen T, Perola M, Niini P, et al. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. Hum Mol Genet 1998; 7: 1453–62

    Article  PubMed  CAS  Google Scholar 

  26. Herrmann SM, Poirier O, Marques-Vidal P, et al. The Leu33/Pro polymorphism (PL(A1)/Pl(A2)) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study: etude cas-temoins de l’infarctus du myocarde. Thromb Haemost 1997; 77: 1179–81

    PubMed  CAS  Google Scholar 

  27. Gardemann A, Humme J, Stricker J, et al. Association of the platelet glycoprotein IIIa Pl(A1)/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost 1998; 80: 214–7

    PubMed  CAS  Google Scholar 

  28. Walter DH, Schachinger V, Elsner M, et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet 1997; 350: 1217–9

    Article  PubMed  CAS  Google Scholar 

  29. Mamotte CD, van Bockxmeer FM, Taylor RR. PIa1/a2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol 1998; 82: 13–6

    Article  PubMed  CAS  Google Scholar 

  30. Abbate R, Marcucci R, Camacho-Vanegas O, et al. Role of platelet glycoprotein PL (A1/A2) polymorphism in restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 82: 524–5

    Article  PubMed  CAS  Google Scholar 

  31. Laule M, Cascorbi I, Stangl V, et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study. Lancet 1999; 353: 708–12

    Article  PubMed  CAS  Google Scholar 

  32. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881–6

    Article  PubMed  CAS  Google Scholar 

  33. de Gaetano G, Cerletti C, Iacoviello L. Pharmacogenetics as a new antiplatelet strategy: platelets in thrombotic and non thrombotic disorders. In: Gresele P, Page CP, Fuster V, et al., editors. Platelets in thrombotic and non-thrombotic disorders: pathophysiology, pharmacology and therapeutics. Cambridge: Cambridge University Press, 2002: 964–77

    Chapter  Google Scholar 

  34. Coller BS, Seligsohn U, Peretz H, et al. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol 1994; 31: 301–11

    PubMed  CAS  Google Scholar 

  35. Coller BS. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions. Thromb Haemost 1999; 82: 326–36

    PubMed  CAS  Google Scholar 

  36. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, et al. The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 2000; 105: 793–802

    Article  PubMed  CAS  Google Scholar 

  37. Feng D, Lindpaintner K, Larson MG, et al. Increased platelet aggregability associated with platelet GPIIIa Pl(A2) polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999; 19: 1142–7

    Article  PubMed  CAS  Google Scholar 

  38. Michelson AD, Furman MI, Goldschmidt-Clermont P, et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013–8

    Article  PubMed  CAS  Google Scholar 

  39. Goldschmidt-Clermont P, Weiss E, Shear W, et al. Platelets from PL(A2)(−) individuals bind more exogenous fibrinogen than platelets from PL(A2)(+) individuals [abstract]. Blood 1996; 88: 26a

    Google Scholar 

  40. Lasne D, Krenn M, Pingault V, et al. Interdonor variability of platelet response to thrombin receptor activation: influence of Pl(A2) polymorphism. Br J Haematol 1997; 99: 801–7

    Article  PubMed  CAS  Google Scholar 

  41. Goodall AH, Curzen N, Panesar M, et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, Pl(A2), Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999; 20: 742–7

    Article  PubMed  CAS  Google Scholar 

  42. Andrioli G, Minuz P, Solero P, et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911–8

    Article  PubMed  CAS  Google Scholar 

  43. Bray PF. Integrin polymorphisms as risk factors for thrombosis. Thromb Haemost 1999; 82: 337–44

    PubMed  CAS  Google Scholar 

  44. Cooke GE, Bray PF, Hamlington JD, et al. Pl(A2) polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253

    Article  PubMed  CAS  Google Scholar 

  45. Undas A, Sanak M, Musial J, et al. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982–3

    Article  PubMed  CAS  Google Scholar 

  46. Szczeklik A, Undas A, Sanak M, et al. Relationship between bleeding time, aspirin and the Pl(A1)/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 965–7

    Article  PubMed  CAS  Google Scholar 

  47. Iacoviello L, Donati MB. Interpretation of thrombosis prevention trial [letter]. Lancet 1998; 351: 1205

    Article  PubMed  CAS  Google Scholar 

  48. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79–85

    Article  PubMed  CAS  Google Scholar 

  49. Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774–80

    Article  PubMed  CAS  Google Scholar 

  50. O’Connor FF, Shields DC, Fitzgerald A, et al. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 2001; 98: 3256–60

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from the Italian Ministry of Health, Rome, Italy (contract no. 211 RF 2002) and by the EU project IMMIDIET QLK1-CT-2000-00100.

The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Research Laboratories, Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

    Augusto Di Castelnuovo, Giovanni de Gaetano, Maria Benedetta Donati &  Licia Iacoviello

Authors
  1. Augusto Di Castelnuovo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni de Gaetano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Benedetta Donati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Licia Iacoviello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Licia Iacoviello.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Castelnuovo, A., de Gaetano, G., Donati, M.B. et al. Platelet Glycoprotein IIb/IIIa Polymorphism and Coronary Artery Disease. Am J Pharmacogenomics 5, 93–99 (2005). https://doi.org/10.2165/00129785-200505020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129785-200505020-00002

Keywords

Search

Navigation